Novel oral therapies are currently being researched – promising data from clinical trials is now available. In the field of approved, subcutaneously administered IL-23 and IL-17 antagonists, current real-world data provide valuable insights for everyday practice. A long-term goal of systemic psoriasis therapy is to erase the inflammatory memory and thus achieve a sustainable cure. Several research projects have therefore focused on tissue-resident memory T-cells.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- NSCLC
Bispecific antibodies for rare EGFR mutations
- Type 2 diabetes - glycemic control and prevention of secondary diseases
Utilizing pleiotropic cardio- and nephroprotective effects of SGLT-2-i and GLP-1-RA
- Subsyndromal anxiety disorders: Family doctor as first point of contact
Practical recommendations for diagnostics and therapy
- Patient-centered rounds in medicine
Aligning care with the patient
- Restless legs syndrome in children
Relationship between restless legs syndrome and growing pains
- Between hope and evidence gaps
Tinnitus and phytotherapy
- Case Report
17-year-old patient with acne fulminans
- Oncology